3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4 Argatroban Factory
Manufacturer Supple Argatroban intermedia:
Ethyl (2R,4R)-4-Methyl-2-Piperidine-carboxylatus CAS 74892-82-3
N-Nitro-1,2,3,4-tetradehydro Argatroban Ethyl Ester CAS 74874-09-2
3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4
Argatroban Monohydrate CAS 141396-28-3
Argatroban Anhydrous CAS 74863-84-6
Nomen chemicum | 3-Methyl-8-Quinolinesulphonyl Chloride |
Synonyma | 3-Methylquinoline-8-Sulfony Chloride |
CAS Number | 74863-82-4 |
CATTUS Number | RF-PI269 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C10H8ClNO2S |
M. Pondus | 241.69 |
Density | 1.4±0.1 g/cm3 |
Index refractivus | 1.63 |
Solubilitas | Solutum in Chloroforme |
Shipping Condition | Uit sub Ambient Temperature |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Crystallina pulveris alba |
Puritas / Analysis Methodus | >98.0% (HPLC) |
Liquescens punctum | 162.0~163.0℃ |
Damnum in Siccatio | <0.50% |
3-Methylquinoline-8-Sulfonic Acid | <1.00% |
Totalis immunditias | <2.00% |
Infrared Imaginis | Conformat ut Structure |
NMR | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Argatrobanum (CAS 74863-84-6). |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine & humore
Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum Chloride 3-Methyl-8-Quinolinesulphonyl (CAS: 74863-82-4) cum qualitate, late in synthesi organica adhibita, synthesis intermediorum pharmaceuticae et pharmaceuticae Ingredientis activae. (API) synthesis.Itmedium est typice in synthesi Argatroban (CAS: 74863-84-6) vel Argatroban Monohydrate (CAS 141396-28-3).
Argatroban (CAS: 74863-84-6) anticoagulans parvum moleculae inhibitoris thrombin directum est.Anno 2000, argatroban licentiatus est ab Administratione Cibus et medicamentis (FDA) prophylaxis vel curatio thrombosis patientibus heparin inductae thrombocytopenia (HIT).Anno 2002 probatum est in usu interventus coronarii percutaneos interventus aegros, qui HIT vel in periculo sunt ad eam enucleandam.Anno 2012, probatum est a MHRA in UK pro anticoagulation in patientibus heparin-ductus thrombocytopenia Type II (HIT) qui therapiam antithromboticam parenterale requirunt.